Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Ainhoa Madariaga , Stefano Marastoni , Ilaria Colombo , Victoria Mandilaras , Michael Cabanero , Jeffrey Bruce , Swati Garg , Lisa Wang , Sarbjot Gill , Neesha C. Dhani , Valerie Bowering , Xuan Li , Amit M. Oza , Anthony M. Joshua , Stephanie Lheureux
Background: Autophagy is a mechanism of resistance to platinum chemotherapy. Itraconazole (Itr), an antifungal agent, can alter cholesterol-trafficking, leading to accumulation of cholesterol in endosomes/lysosomes and resulting in cancer cell death. Itr is also involved in regulation of angiogenesis, mTOR and Hedgehog pathways. In preclinical studies the Itr effect can be enhanced by combining it with the autophagy inhibitor hydroxychloroquine (H). Drug repurposing studies with Itr have shown a signal of activity in prostate, lung and basal cell carcinoma. Methods: A rolling-6 phase I design was used to enroll patients (pts) with platinum-resistant/refractory EOC. Pts received Itr 300mg twice daily (BID) with H as per dose escalation schedule (range 200mg BID- 600mg BID), continuously in a 28-day cycle. Primary objective was establishment of MTD; secondary objective was objective response rate, progression free survival (PFS). Pre- and on-treatment biopsies were mandatory to evaluate exploratory objectives assessing effect on apoptosis/proliferation, angiogenesis, cholesterol metabolism and mechanism of cytotoxicity. RNAseq and IHC was performed in the sequential biopsies. Results: 11 pts were enrolled, 9 evaluable for efficacy. Histology was high 91% and low-grade serous 9%. Median lines of prior therapy was 7. RP2D was Itr 300mg BID and H 600mg BID. 1 DLT was seen in dose-level 2 was grade 3 hypertension. Other grade ≥3 related toxicity were grade 3 hypokalemia and grade 4 QTc prolongation (1 pt, dose-level 3). No objective responses were observed and 1 pt had stable disease. Median PFS was 1.6 months (1-1.7). Pre- and on-treatment biopsy was available for 10 pts. Increase in autophagy related protein, LC3, P62 and lysosomal marker, LAMP1, expression by IHC was identified in 3 pts. RNAseq revealed no differences between pre and on treatment samples in cholesterol homeostasis, angiogenesis, lysosomal-autophagy, PI3K-mTOR pathways. Conclusions: The combination of Itr and H was feasible but did not show antitumour activity in this heavily pre-treated platinum resistant EOC population. Increase of IHC expression in autophagy related proteins was detected in 30% of pts but did not correlate with patient benefit. Clinical trial information: NCT03081702
AE term | Grade 1-2 % | Grade 3-4 % |
---|---|---|
Nausea | 36 | 0 |
Diarrhea | 27 | 0 |
Dry skin | 27 | 0 |
Fatigue | 27 | 0 |
Vomiting | 27 | 0 |
ALT increase | 18 | 0 |
Anemia | 18 | 0 |
Anorexia | 18 | 0 |
AST increase | 18 | 0 |
Constipation | 18 | 0 |
QT corrected interval prolonged | 9 | 9 |
Neutropenia | 18 | 0 |
Pruritus | 18 | 0 |
White blood cell decrease | 18 | 0 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Breakthrough
First Author: Gulam Abbas Manji
2021 Gastrointestinal Cancers Symposium
First Author: Sukeshi Patel Arora
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Chetan Vakkalagadda
2023 ASCO Annual Meeting
First Author: Andrew H. Ko